Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer Market

Non-Muscle Invasive Bladder Cancer (NMIBC) is a common, heterogeneous disease associated with high rates of recurrence that usually requires lifelong surveillance. The cancer is found in the tissue, which lines the inner surface of the bladder wherein the bladder muscle is not involved.


Approximately 70–80% patients with newly diagnosed bladder cancer present with a form of non-muscle-invasive bladder cancer (NMIBC), such as non-invasive papillary tumour (pTa), carcinoma in situ (CIS; pTis), or early invasive tumour (non-muscle invasive; pT1). These tumours characteristically recur in 50–70% of cases, with only approximately 10–20% of cases progressing to muscle-invasive bladder cancer (MIBC).


Non-Muscle Invasive Bladder Cancer Epidemiological Segmentation 

The Epidemiological Segmentation of Non-Muscle Invasive Bladder Cancer in 7MM from 2017 to 2030 is segmented as:- 

  • Prevalent cases of Bladder Cancer
  • Diagnosed Prevalent cases of Bladder Cancer
  • Diagnosed Prevalent cases of NMIBC
  • Age-specific Diagnosed Prevalence of NMIBC
  • Tumour (T) stage-specific Diagnosed Prevalence of NMIBC
  • Grade-specific Diagnosed Prevalence of NMIBC
  • Risk-specific Diagnosed Prevalence of NMIBC


Non-Muscle Invasive Bladder Cancer Epidemiology 

  • The total diagnosed prevalent population of NMIBC in 7MM in 2017 was 533,263
  • EU5 countries occupied approximately 45.90% of the patient pool amongst 7MM in 2017


Non-Muscle Invasive Bladder Cancer Market

The market size of Non-Muscle Invasive Bladder Cancer in 7MM in 2017 was USD 1,454 Million  


Non-Muscle Invasive Bladder Cancer Market Drivers

  • Imminent Launches
  • The upsurge in Research and Development
  • Enriched Understanding
  • Increased Incidence

 

Non-Muscle Invasive Bladder Cancer Market Barriers

  • High Cost of Therapy
  • Expression Heterogeneity
  • Lack of Approved Therapies


Non-Muscle Invasive Bladder Cancer Emerging Drugs

The emerging drugs of the Non-Muscle Invasive Bladder Cancer market are 

  • Vicinium
  • Adstiladrin (nadofaragene firadenovec/Syn3)
  • Tecentriq (atezolizumab)
  • Sasanlimab (PF-06801591) + BCG
  • Apaziquone
  • Opdivo (nivolumab)
  • Imfinzi (durvalumab)
  • VesiGel (UGN-102/mitomycin gel)
  • Pemigatinib
  • CG0070
  • Erdafitinib
  • Revlimid (lenalidomide): N-803 (ALT-803)
  • TLD-1433
  • Bavencio (avelumab + BCG)
  • Alpha1H
  • LiPax
  • Imfinzi (durvalumab) + S-488210/S-488211

And many others. 


Non-Muscle Invasive Bladder Cancer Key Players

The key players in the Non-Muscle Invasive Bladder Cancer market are

  • Sesen Bio
  • FKD Therapies Oy
  • Ferring Pharmaceuticals
  • Hoffmann-La Roche
  • Pfizer
  • Spectrum Pharmaceuticals
  • Bristol-Myers Squibb
  • AstraZeneca
  • UroGen Pharma
  • Incyte Corporation
  • CG Oncology
  • Janssen Research & Development
  • Celgene Corporation
  • ImmunityBio
  • Altor Biosciences
  • Theralase
  • EMD Serono
  • Hamlet Pharma
  • TesoRx Pharma

And many others.